Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

256
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
256
Bioavailability: Overview01:13

Bioavailability: Overview

2.8K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.8K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

73
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
73

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining Engineering Precision with Clinical Relevance: A Novel Dual Framework for Assessing Pedicle Screw Accuracy in Spine Surgery.

Journal of clinical medicine·2026
Same author

Distinct neuronal alterations distinguish two subtypes of sporadic Creutzfeldt-Jakob disease with shared dysfunctional pathways.

The Journal of clinical investigation·2026
Same author

Collective photon emission and ferroelectric exciton ordering near Mott insulating state in WSe<sub>2</sub>/WS<sub>2</sub> heterobilayers.

Nature materials·2026
Same author

Self-induced superradiant masing.

Nature physics·2026
Same author

Self-Bound Superfluid Membranes and Monolayer Crystals of Ultracold Polar Molecules.

Physical review letters·2025
Same author

Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method.

mAbs·2025

Related Experiment Video

Updated: Jul 2, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Patient-centric Comparability Assessment of Biopharmaceuticals.

Markus Blümel1, Ruth Cordoba-Rodriguez2, James A Carroll3

  • 1Novartis Pharma AG, Biologics Analytical Development, Lichtstrasse 35, CH-4056 Basel, Switzerland.

Journal of Pharmaceutical Sciences
|February 19, 2024
PubMed
Summary

Implementing manufacturing process changes for biological products requires a risk-based comparability assessment. This review consolidates industry best practices for designing and executing these assessments throughout the product lifecycle.

Keywords:
Analytical comparabilityAntibody drugsBiopharmaceutical characterizationCMCPatient-centricRegulatory scienceStabilityStandards

More Related Videos

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.1K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.0K

Related Experiment Videos

Last Updated: Jul 2, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.1K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.0K

Area of Science:

  • Biopharmaceutical manufacturing
  • Process development
  • Quality control

Background:

  • Manufacturing process changes are common throughout a biological product's lifecycle.
  • The impact of these changes on product quality necessitates careful comparability assessment.
  • Existing industry approaches require consolidation for consistent application.

Purpose of the Study:

  • To review and consolidate industry approaches for biological product comparability assessment.
  • To provide guidance on risk-based strategies for process changes.
  • To inform regulatory discussions and industry best practices.

Main Methods:

  • A working group reviewed and consolidated existing industry approaches.
  • The review focused on traditional protein-based biological products.
  • Key topics included risk evaluation, study design, data assessment, and regulatory strategy.

Main Results:

  • A risk-based approach is essential for comparability assessment after process changes.
  • Comparability assessment strategies should be adapted based on the stage of the product lifecycle.
  • Consolidated insights cover risk evaluation, study design, data assessment, and regulatory submission.

Conclusions:

  • Leveraging these consolidated practices can aid companies in designing and executing comparability assessments.
  • This review facilitates informed discussions with global regulatory agencies.
  • Standardized approaches enhance the consistency and reliability of biological product comparability.